Cyclacel Pharmaceuticals, Inc. (CYCC): Price and Financial Metrics

Cyclacel Pharmaceuticals, Inc. (CYCC): $0.90

-0.01 (-0.68%)

POWR Rating

Component Grades













Add CYCC to Watchlist
Sign Up

Industry: Biotech



in industry

CYCC Stock Price Chart Interactive Chart >

Price chart for CYCC

CYCC Price/Volume Stats

Current price $0.90 52-week high $3.99
Prev. close $0.91 52-week low $0.53
Day low $0.89 Volume 74,395
Day high $0.94 Avg. volume 83,370
50-day MA $0.80 Dividend yield N/A
200-day MA $1.26 Market Cap 11.33M

Cyclacel Pharmaceuticals, Inc. (CYCC) Company Bio

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Its oncology development programs also comprise sapacitabine, an oral nucleoside analogue prodrug that is in Phase 1/2 combination study with seliciclib, a CDK inhibitor in patients with BRCA mutations; with olaparib, a poly ADP-ribose polymerase inhibitor in BRCA mutation positive patients with breast cancer; and Phase III clinical trial for the treatment of acute myeloid leukemia. In addition, the company's oncology development programs include seliciclib, a CDK inhibitor that is in all-oral Phase 1/2 combination study with sapacitabine for BRCA mutations. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias; and collaboration, licensing, and supply agreement with ManRos Therapeutics SA for the development and commercialization of oral seliciclib capsules for the treatment of cystic fibrosis. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.

CYCC Latest News Stream

Event/Time News Detail
Loading, please wait...

CYCC Latest Social Stream

Loading social stream, please wait...

View Full CYCC Social Stream

Latest CYCC News From Around the Web

Below are the latest news stories about CYCLACEL PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CYCC as an investment opportunity.

Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces Key Business Objectives for 2023

– Determination of Recommended Phase 2 Dose and Start of Phase 2 in 1Q 2023 for Oral Fadraciclib – – 2/3 Partial Responses in Lymphoma and 11/15 Stable Disease in Advanced Solid Tumors – – Expecting Key Data Readouts for Oral Fadraciclib in 2023 – – Expecting Preliminary Safety and Efficacy Update for Oral Plogosertib (formerly CYC140) in Advanced Solid Tumors in 1H 2023 – – Existing Cash Until End of 2023 Support Multiple Data Readouts – BERKELEY HEIGHTS, N.J., Jan. 05, 2023 (GLOBE NEWSWIRE) --

Yahoo | January 5, 2023

Cyclacel Pharmaceuticals to Present at Biotech Showcase and Participate in a Corporate Access Event During the J.P. Morgan Healthcare Conference in January 2023

BERKELEY HEIGHTS, N.J., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that the Company plans to present at the Biotech Showcase and host institutional investor and partnering meetings at this event and a Corporate Access Event organized by LifeSci Partners. Both in-person events are taking place January 9-11, 2023

Yahoo | December 15, 2022

Cyclacel pulls the plug on Daiichi-partnered chemo — 8 years after a failed PhIII in AML

Hovering around penny stock territory, New Jersey-based Cyclacel Pharmaceuticals $CYCC said yesterday it''s finally going to call it quits on a Daiichi Sankyo-partnered cancer drug candidate that saw a Phase III flop in acute myeloid leukemia in late 2014. First licensed from Daiichi back in 2003, Cyclacel says it now

Endpoints News | November 10, 2022

Cyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

- Oral Fadraciclib Daily Dosing Well Tolerated in 18 Evaluable Patients Treated in Dose-Escalation of Phase 1/2 Trial in Advanced Solid Tumors and Lymphoma -

GlobeNewswire | November 9, 2022

Cyclacel Pharmaceuticals, Inc. (CYCC) Q3 2022 Earnings Call Transcript

Cyclacel Pharmaceuticals, Inc. (NASDAQ:NASDAQ:CYCC) Q3 2022 Earnings Conference Call November 09, 2022 04:30 PM ET Company Participants Irina Koffler - LifeSci Advisors Spiro Rombotis -…

Seeking Alpha | November 9, 2022

Read More 'CYCC' Stories Here

CYCC Price Returns

1-mo 34.93%
3-mo -25.00%
6-mo -27.42%
1-year -71.70%
3-year -93.10%
5-year -97.24%
YTD 34.93%
2022 -82.85%
2021 -50.19%
2020 -41.72%
2019 10.74%
2018 -65.23%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7371 seconds.